Version June 2024
| IHC antibody | Expected result | ||
| Paget's disease of the breast (PDB) | Malignant melanoma | Squamous carcinoma in situ (Bowen's disease) | |
| CK7 | Positive-diffuse | Negative | Negative/focal positive |
| CEA polyclonal | Positive | Negative | Negative/rare positive |
| p63 | Negative* | Negative | Positive |
| SOX10¶ | Negative | Positive | Negative |
| Additional markers that may be useful additions to the above IHC antibodies | |||
| Mart-1 (Melan A)¶ | Negative | Positive | Negative |
| S-100¶ | Negative/weak positive | Positive/rare negative | Negative |
| EMA | Positive | Negative | Positive |
| HER2 | PositiveΔ | Negative | Negative |
| HMWCK | Negative* | Negative | Positive |
IHC: immunohistochemical; CK7: cytokeratin 7; CEA: carcinoembryonic antigen; EMA: epithelial membrane antigen; HMWCK: high-molecular-weight cytokeratin (eg, 34betaE12 or CK5/6).
* Triple-negative breast cancer (TNBC) expresses p63 and HMWCK.
¶ Dermal and intraepithelial melanocytes will express SOX10, Mart-1, and S-100.
Δ PDB is usually (80 to 90%) HER2 positive but may be estrogen receptor positive or TNBC in a low proportion of cases.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
